In the clinical management of pediatric solid tumors, histological examination of tumor tissue obtained by a biopsy remains the gold standard to establish a conclusive pathological diagnosis. The DNA methylation pattern of a tumor is known to correlate with the histopathological diagnosis across cancer types and is showing promise in the diagnostic workup of tumor samples. This methylation pattern can be detected in the cell-free DNA. Here, we provide proof-of-concept of histopathologic classification of pediatric tumors using cell-free reduced representation bisulfite sequencing (cf-RRBS) from retrospectively collected plasma and cerebrospinal fluid samples. We determined the correct tumor type in 49 out of 60 (81.6%) samples starting from minute amounts (less than 10 ng) of cell-free DNA. We demonstrate that the majority of misclassifications were associated with sample quality and not with the extent of disease. Our approach has the potential to help tackle some of the remaining diagnostic challenges in pediatric oncology in a cost-effective and minimally invasive manner.
Introduction
The diagnostic work-up of pediatric cancer patients with solid tumors requires a number of investigations to obtain a full diagnosis and a complete staging. Most imaging and tumor marker investigations are of low specificity and do not result in a definitive diagnosis. Thus, in most cases, a histopathological examination of a surgically derived tumor biopsy is required.
Many of the pediatric tumors share a "small blue" histology and show few lineage-specific morphological features. Hence, extensive immunohistochemistry staining is often required to establish a diagnosis. Nevertheless, some types of embryonic tumors or sarcomas remain hard to classify correctly. In the context of international frontline clinical trial protocols tumor specimens are often sent for central pathology review. In a small percentage of patients, discrepancy in either stage or diagnosis can result in suboptimal treatment1,2. In pediatric renal tumors, the rate of misdiagnosis was estimated to range from 3.5% to 17% based on multicenter clinical trials1. Limited tissue availability due to fine needle biopsy sampling can further complicate the diagnostic work-up. Furthermore, for some types of pediatric tumors, sampling of the tumor is not routinely recommended in some treatment protocols (e.g. SIOP protocol for treatment of renal tumors3,4) or is deemed too risky due to the location (e.g. diffuse intrinsic pontine glioma) or clinical condition of the patient (e.g. contra-indications for anesthesia due to extensive disease). Thus, therapy needs to be started empirically based on imaging and clinical characteristics alone, increasing the odds for misdiagnosis.
The epigenetic signal of primary tissue samples is currently being explored to complement classical histopathological analysis. This epigenetic signal seems to be highly tissue-specific5- 7 as opposed to most mutational or copy number alterations. This tissue specificity is the dominant remaining signal after malignant transformation, resulting in a unique fingerprint of DNA for different tumor entities8, 9. For example, the DNA methylation signal contributed to obtaining the correct diagnosis in 25 out of 30 cases in a cohort of translocation-negative Ewing sarcoma samples10. Among brain tumors, primitive neuro-ectodermal tumors of the central nervous system (CNS-PNETs) are notoriously difficult to diagnose based on histology alone. DNA methylation revealed that this entity is actually composed of multiple known and previously unknown tumor types11. Furthermore, in a large cohort of 1155 prospectively collected brain tumor samples, 12% of histopathological diagnoses could be adjusted based on tumor DNA methylation characteristics12. In medulloblastoma, prospective clinical trials are currently ongoing to test whether the adaptation of treatment based on new multi-omics (including DNA methylation) improves event-free survival (NCT02066220).
Recently, analysis of cell-free tumor-derived DNA (ctDNA) isolated from liquid biopsies including blood has emerged as a complementary assay for tumor tissue genomic profiling13.
Several groups have investigated the use of cell-free DNA methylation for noninvasive diagnosis of both benign14 and malignant15 conditions. For example, Kang et al. developed CancerLocator8, an algorithm based on the epigenetic signature determined on whole genome bisulfite sequencing (WGBS) to classify cell-free DNA of adult cancer patients to their corresponding tumor tissue. Through data deconvolution, the CancerLocator method was able to correctly classify samples, even if they had a low percentage of circulating tumor DNA, outperforming standard machine-learning approaches.
Although tumor classification from the epigenetic cfDNA profile is possible, the high cost of WGBS limits its use in routine clinical diagnostics and follow-up. Reduced representation bisulfite sequencing (RRBS) is a cost-effective alternative whereby only a small informative fraction of the genome is surveyed 16. Enrichment of CpG-rich sites by digesting DNA with the MspI restriction enzyme (cuts 5'-C/CGG-3'), followed by DNA fragment size-selection is a commonly applied strategy of RRBS. This method was redesigned by De Koker et al. 17 to allow single tube RRBS library preparation on low input levels (10 ng) of low-quality and/or fragmented DNA.
Our study investigates whether the methylome profile generated with RRBS on cell-free DNA (cf-RRBS) is capable of classifying pediatric tumors according to their histopathological diagnosis. To this end, we profiled plasma or cerebrospinal fluid of 59 patients with pediatric cancer. This profile was used to classify the sample according to a reference dataset built from publicly available methylome data of pediatric tumors of known histology. We further explored the tumor copy number profile extracted from cf-RRBS comparing it against the copy number profile obtained from shallow whole genome sequencing data.
Materials and methods

Patients and samples
Pediatric cancer patients (median age 46 months [18.5 -114.5] ) were included retrospectively if plasma or CSF was available at diagnosis (n = 58) or at relapse (n = 1). For one case Wilcoxon rank sum test was used to test for significance with alpha specified at 0.05.
Sample collection and processing
Ghent University Hospital. Whole blood was collected in citrate tubes (Greiner Bio-One, n = 16). Plasma was obtained after 1 x 8 min centrifugation at 1885 g. The time between blood collection and plasma preparation was not documented. All plasma samples were stored at −80 °C until processing for cfDNA extraction. CSF was collected into tubes without additives.
The CSF was stored at -80 °C until further processing for cfDNA extraction.
Prinses Máxima Center. Whole blood from all patients was collected in EDTA Vacutainer
tubes (BD Biosciences). Plasma was obtained after 1 x 10 min centrifugation at 1375 g with centrifuge acceleration and without deceleration. The plasma was stored at -20 °C until processing for cfDNA extraction. Plasma was prepared within 24 hours after blood collection.
Prague Motol University Hospital. Whole blood from all patients was collected in EDTA
Vacutainer tubes (BD Biosciences). Plasma was obtained after 1 x 10 min centrifugation at by a subsequent centrifugation step of 1 x 10 minutes at 16,000 g at room temperature. The plasma was stored at −80 °C until processing for cfDNA extraction. Before the first centrifugation step, 2.5% (v/v) of a 10% formaldehyde solution was added. Plasma was prepared within 4 hours after blood draw.
Institut Curie. Whole blood was collected in EDTA tubes. Plasma was obtained after 1 x 20 min centrifugation at 2000 g at room temperature, centrifuge acceleration, and deceleration was set to two, followed by a subsequent centrifugation step of 1 x 2 minutes at 16,000 g at room temperature. The plasma was stored at −80 °C until processing for cfDNA extraction. figures. Because this interpretation is inherently subjective, the coefficient of determination (R2) and Cohen's Kappa coefficient between both observers was calculated. R2 between the two observers was 0.91. Samples with a cfDNA/HMW ratio less than 1 were labeled as "high HMW contamination", samples with a cfDNA/HMW ratio between 1 and 5 "medium HMW contamination" and samples with a cfDNA/HMW ratio >5 as "low HMW contamination".
Cell-free DNA extraction
Cohen's Kappa coefficient with equal weights between the two observers was 0.798 (p < 0.001). We then evaluated these cut-offs by collecting blood from 3 healthy volunteers in EDTA tubes. The tubes were either processed immediately or left standing at room temperature for 24 or 72 hours. The blood tubes that were processed immediately all showed a cfDNA/HMW ratio above 5 (11.48, 9. 01 and 36.03, respectively). The cfDNA/HMW ratio of the EDTA tubes that were left standing for 24h were all between 1 and 5 (5.02, 1.37 and 4.05, respectively) and the cfDNA/HMW ratio of the tubes that were left standing for 72h were all lower than 1 (0.33, 0.20 and 0.42, respectively). 3 ).
RRBS library construction
Sequencing quality control and mapping
After sequencing, bcl files were demultiplexed using bcl2fastq v2. 19 
Copy number alteration profiling
For each sample, shallow whole genome sequencing (sWGS) data was available to assess copy number alterations (CNAs) in cfDNA. After DNA isolation, cfDNA was processed as probes on the HM450K array. In our cohort, these regions were consistently covered across all samples, except for 8 regions that were not covered in any of the samples (supplementary data).
t-SNE visualizations
Clustered and processed beta values from the 9 reference entities were grouped in a single data matrix with Python v3. 6 
Results
The methylation signature is pediatric tumor type specific. Similar to the t-SNE plots as described by Capper et al. 12 , we applied t-SNE dimensionality reduction (Figure 1 ) to the extracranial reference dataset to assess the feasibility of establishing the diagnosis of extracranial pediatric cancers based on the methylation signature from public data. Separate clusters based on the histopathological diagnosis could be visually identified. Furthermore, Ewing sarcoma samples from three different public datasets cluster together, indicating that laboratory and/or method batch effects from different publicly available datasets are not dominating the classification. In addition, some individual tumor samples cluster with white blood cells (WBC). We hypothesize that either these biopsies may have been contaminated with leukocytes during surgery, or the tumor might have been rich in infiltrating lymphocytes.
Nevertheless, to avoid bias, these samples were not excluded from the reference dataset. In addition, we were able to distinguish medulloblastoma (n = 3/3) from an atypical teratoidrhabdoid tumor using the methylation profile of CSF cfDNA. [3.20 -51 .80], p = 0.39, Figure 5 ).
Classification of cell-free
Further investigation into the misclassified samples revealed that the majority of these samples had evidence for medium to high HMW contamination (cfDNA/HMW DNA ratio less than 5). In samples with low HMW DNA contamination, the classification accuracy was 94.59% (n = 35/37) ( Figure 5 ). In samples with medium to high HMW DNA contamination, the classification accuracy was 60.86% (n = 14/23). Copy number analysis is feasible using cf-RRBS data. Copy number alterations could be detected with shallow WGS in 42 out of 60 samples (Figure 3, Figure 4 ). The concordance between estimated tumor fraction using methylation profiling data and the estimated tumor fraction by ichorCNA analysis of sWGS profiles was moderate for samples with low to medium HMW DNA contamination (Spearman r 0.77 and 0.78, respectively, Figure 6 ). Importantly, MYCN amplification could be observed with both the sWGS and cf-RRBS CNA profiles in the three neuroblastoma samples with confirmed MYCN amplification. If CNAs were present in cf-RRBS (n = 32), the correlation of the CNA profile with sWGS was high (0.87 [0.82 -0.94]).
However, the reverse was not true; several samples (n = 10) showed CNAs according to sWGS but none using cf-RRBS. In the group with discordant CNA profiles between cf-RRBS samples that showed no CNA using sWGS had evidence for CNA based on cf-RRBS data ( Figure 6 ). 
Discussion
We show that classification based on cfDNA methylation profile as determined by cf-RRBS is feasible for the subset of extra-and intracranial pediatric cancer entities included in this study.
Overall, we are able to correctly classify 49 out of 60 (81.6%) samples. We are able to identify specific recurrent genomic alterations such as MYCN amplification in neuroblastoma and differentiate between alveolar and embryonal rhabdomyosarcoma subtype from these same data. Importantly, only 1-10 ng of cfDNA is required for the cf-RRBS analysis, making clinical implementation in pediatric practice feasible from just 200 µl of plasma. Furthermore, costper-sample was calculated at a conservative 180 euro, including sample collection, DNA isolation, library preparation and sequencing (excluding personnel costs), favoring our techniques routine application over the substantially more expensive gold-standard of whole genome bisulfite sequencing.
In our study, misclassifications seemed to be predominantly associated with sample quality.
Samples of low quality had a higher amount of high molecular weight, non-cell-free DNA and this artificially reduced the estimated tumor fraction, resulting in a more challenging classification. Inherent to the retrospective multicenter nature of our study is a lack of control over the pre-analytical variables such as the blood tube used, the handling of the collection tube, any delay between collection and downstream processing and the SOP used in cfDNA isolation. Preservation tubes (e.g. Streck Cell-Free DNA BCT, Streck) have been developed to stabilize the cfDNA and avoid high molecular weight DNA contamination. However, it is currently unknown to what extent the preservation medium in these tubes alters the methylation profile of the cfDNA or hampers its downstream processing for cf-RRBS.
Furthermore, classification accuracy may be improved for samples with a very low ctDNA fraction given a more sensitive computational deconvolution algorithm, a more robust reference dataset or a combination of genomic and epigenomics-based classification.
Interestingly, in our study, the estimated ctDNA fraction was not associated with extent of disease. This is in contrast to the adult oncology field, where it has often been suggested that cfDNA based assays are mainly of value in high stage, metastatic disease31. This may depend on the tumor entity, but should further be explored in future, prospective studies.
Furthermore, we could correctly classify 9 out of 18 samples with a neutral cfDNA CNA profile.
This hints at an improved sensitivity of methylation profiling over CNA profiling in cfDNA samples with a low tumor fraction.
Other efforts exploring cell-free DNA in pediatric cancer have focused on detection of copy number aberrations, structural variants32,33 and mutations34. However, these alterations come with low specificity for classification of pediatric solid tumors according to their histopathological diagnosis35. In addition, there is a high interest to develop a screening test based on cfDNA methylation in adult oncology36. Due to the rarity of cancer in children, we do not see our test as a screening tool, but rather as a complementary diagnostic test for children for whom a classic biopsy is unfeasible or of low quality. Indeed, it could improve the diagnosis of tumor types with very similar histology (e.g. small round blue cell tumors) as illustrated by the distinction of MRT, CCSK and Wilms tumor in this study. This could potentially impact on clinical decision making for patients with renal tumors who are usually not biopsied before therapy start. Another major application is in the minimally-invasive classification of brain tumors, where tumor tissue methylation profiling is being pitched as a way to improve tumor classification11,12 but high quality and sufficiently large biopsies are hard to obtain.
While we provide proof-of-concept for the applicability of the cf-RRBS assay, there are several limitations to our study. Building a classifier from public datasets from many different laboratories will result in batch and platform effects that will inevitably bias the results of this study. In addition, our current classifier is also limited to entities of whom public data is available. The public data available was generated with different strategies (array, RRBS, WGBS) potentially resulting in a suboptimal classifier. Ideally, a reference atlas of RRBS or WGBS data from a wide array of pediatric cancers and healthy children should be generated to further improve our classifier. Implementation into clinical trials or routine diagnostics will require additional adaptations to our method. In future validation studies, the inclusion of children without cancer will be necessary to calculate the specificity of the assay. Furthermore, in its current iteration our assay has a theoretical turn-around-time of 5 working days which is too long for its use in real-time clinical decision making.
In recent years, a number of alternatives to WGBS for cfDNA methylation profiling were developed. The Roche SeqCap Epi assay is a capture-based technique and is able to assess the methylation profile of cfDNA by enriching for CpG dense genomic areas. However, this technique has a lower cost-effectiveness compared to cf-RRBS, is difficult to implement in a routine clinical setting and the protocol is cumbersome and time-consuming17. Single cell RRBS (scRRBS) has also been suggested as a cost-effective alternative to classical RRBS and WGBS for low-input samples, but is more labor-intensive15. More recently, cfMeDIP-seq37 was used to detect and classify adult cancers in an early stage. However, as this method is based on immunoprecipitation it has its own drawbacks38. These techniques all cover different parts of the methylome, and the optimal technique for sensitive tumor detection remains yet to be demonstrated.
In conclusion, while a thorough prospective evaluation is required to delineate and establish the true value of the technique and its clinical application, this proof-of-concept study suggests a role for cf-RRBS as a cost-effective addition to the diagnostic toolbox in pediatric oncology.
